A hepatitis C virus-host interaction involved in viral replication: Toward the identification of antiviral targets

Japanese Journal of Infectious Diseases

Volumn 63, Issue 5, 2010, Pages 307-311

  Suzuki, Tetsuro ^a,b  

^a HAMAMATSU UNIVERSITY SCHOOL OF MEDICINE   (Japan)

^b NATIONAL INSTITUTE OF INFECTIOUS DISEASES   (Japan)

Author keywords

[No Author keywords available]

Indexed keywords

ALPHA INTERFERON; ANTIVIRUS AGENT; BMS 790052; BOCEPREVIR; CILUPREVIR; INTERFERON; PEGINTERFERON; RIBAVIRIN; TELAPREVIR; UNCLASSIFIED DRUG;

ANTIVIRAL ACTIVITY; ARTICLE; CARDIOTOXICITY; CLINICAL TRIAL; DEPRESSION; DRUG EFFICACY; DRUG MECHANISM; DRUG RESEARCH; DRUG RESPONSE; DRUG SAFETY; DRUG TARGETING; DRUG TOLERABILITY; FLU LIKE SYNDROME; HEMOLYTIC ANEMIA; HEPATITIS C; HEPATITIS C VIRUS; HUMAN; IMMUNOMODULATION; INTERNAL RIBOSOME ENTRY SITE; NONHUMAN; OPEN READING FRAME; PATHOPHYSIOLOGY; VIROGENESIS; VIRUS CELL INTERACTION; VIRUS GENOME; VIRUS LOAD; VIRUS REPLICATION;

ANTIVIRAL AGENTS; DRUG DISCOVERY; HEPACIVIRUS; HEPATITIS C; HOST-PATHOGEN INTERACTIONS; HUMANS; VIRUS REPLICATION;

EID: 77957736279     PISSN: 13446304     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (69)

1. Poynard, T., Yuen, M.F., Ratziu, V., et al. (2003): Viral hepatitis C. Lancet, 362, 2095-2100.
2. Umemura, T. and Kiyosawa, K. (2007): Epidemiology of hepatocellular carcinoma in Japan. Hepatol. Res., 37 (Suppl. 2), S95-S100.
3. Wasley, A. and Alter, M.J. (2000): Epidemiology of hepatitis C: geographic differences and temporal trends. Semin. Liver Dis., 20, 1-16.
4. Elloumi, H., Houissa, F., Hadj, N.B., et al. (2007): Sudden hearing loss associated with peginterferon and ribavirin combination therapy during hepatitis C treatment. World J. Gastroenterol., 13, 5411-5412.
5. Davis, G.L., Wong, J.B., McHutchison, J.G., et al. (2003): Early virologic response to treatment with peginterferon alfa-2b plus ribavirin in patients with chronic hepatitis C. Hepatology, 38, 645-652.
6. Bukh, J., Purcell, R.H. and Miller, R.H. (1992): Sequence analysis of the 5' noncoding region of hepatitis C virus. Proc. Natl. Acad. Sci. USA, 89, 4942-4946.
7. Honda, M., Beard, M.R., Ping, L.H., et al. (1999): A phylogenetically conserved stem-loop structure at the 5' border of the internal ribosome entry site of hepatitis C virus is required for capindependent viral translation. J. Virol., 73, 1165-1174.
8. Tsukiyama-Kohara, K., Iizuka, N., Kohara, M., et al. (1992): Internal ribosome entry site within hepatitis C virus RNA. J. Virol., 66, 1476-1483.
9. Ito, T. and Lai, M.M. (1999): An internal polypyrimidine-tractbinding protein-binding site in the hepatitis C virus RNA attenuates translation, which is relieved by the 3'-untranslated sequence. Virology, 254, 288-296.
10. Kolykhalov, A., Agapov, E.V., Blight, K.J., et al. (1997): Transmission of hepatitis C by intrahepatic inoculation with transcribed RNA. Science, 277, 570-574.
11. Tanaka, T., Kato, N., Cho, M.-J., et al. (1995): A novel sequence found at the 3' terminus of hepatitis C virus genome, Biochem. Biophys. Res. Commun., 215, 744-749.
12. Masaki, T., Suzuki, R., Murakami, K., et al. (2008): Interaction of hepatitis C virus nonstructural protein 5A with core protein is critical for the production of infectious virus particles. J. Virol., 82, 7964-7976
13. Appel, N., Zayas, M., Miller, S., et al. (2008): Essential role of domain III of nonstructural protein 5A for hepatitis C virus infectious particle assembly. PLoS Pathog., 4, e1000035.
14. Tellinghuisen, T.L., Foss, K.L. and Treadaway, J. (2008): Regulation of hepatitis C virion production via phosphorylation of the NS5A protein. PLoS Pathog., 4, e1000032.
15. Schinazi, R.F., Bassit, L. and Gavegnano, C. (2010): HCV drug discovery aimed at viral eradication. J. Viral Hepat., 17, 77-90
16. Sarrazin, C. and Zeuzem, S. (2010): Resistance to direct antiviral agents in patients with hepatitis C virus infection. Gastroenterology, 138, 447-462.
17. Lemon, S.M., McKeating, J.A., Pietschmann, T., et al. (2010): Development of novel therapies for hepatitis C. Antiviral Res., 86, 79-92.
18. Lamarre, D., Anderson, P.C., Bailey, M., et al. (2003): An NS3 protease inhibitor with antiviral effects in humans infected with hepatitis C virus. Nature, 426, 186-189.
19. Summa V. (2008): VX-950 (Vertex/Mitsubishi). Curr. Opin. Investig. Drugs, 6, 831-837.
20. Yi, M., Tong, X., Skelton, A., et al. (2006): Mutations conferring resistance to SCH6, a novel hepatitis C virus NS3/4A protease inhibitor. Reduced RNA replication fitness and partial rescue by second-site mutations. J. Biol. Chem., 281, 8205-8215.
21. Gao, M., Nettles, R.E., Belema, M., et al. (2010): Chemical genetics strategy identifies an HCV NS5A inhibitor with a potent clinical effect. Nature, 465, 96-100.
22. Suzuki, T., Ishii, K., Aizaki, H., et al. (2007): Hepatitis C viral life cycle. Adv. Drug Deliv. Rev., 59, 1200-1212.
23. Anwar, A., Ali, N., Tanveer, R., et al. (2000): Demonstration of functional requirement of polypyrimidine tract-binding protein by SELEX RNA during hepatitis C virus internal ribosome entry site-mediated translation initiation. J. Biol. Chem., 275, 34231-34235.
24. Ali, N., Pruijn, G.J., Kenan, D.J., et al. (2000): Human La antigen is required for the hepatitis C virus internal ribosome entry site-mediated translation, J. Biol. Chem., 275, 27531-27540.
25. Ali, N. and Siddiqui, A. (1997): The La antigen binds 5' Noncoding region of the hepatitis C virus RNA in the context of the initiator AUG codon and stimulates internal ribosome entry sitemediated translation. Proc. Natl. Acad. Sci. USA, 94, 2249-2254.
26. Isoyama, T., Kamoshita, N., Yasui, K., et al. (1999): Lower concentration of La protein required for internal ribosome entry on hepatitis C virus RNA than on poliovirus RNA. J. Gen. Virol., 80, 2319-2327.
27. Isken, O., Baroth, M., Grassmann, C.W., et al. (2007): Nuclear factors are involved in hepatitis C virus RNA replication. RNA, 13, 1675-1692.
28. Gontarek, R.R., Gutshall, L.L., Herold, K.M., et al. (1999): hnRNP C and polypyrimidine tract-binding protein specifically interact with the pyrimidine-rich region within the 3'NTR of the HCV RNA genome. Nucleic Acids Res., 27, 1457-1463.
29. Hahm, B., Kim, Y.K., Kim, J.H., et al. (1998): Heterogeneous nuclear ribonucleoprotein L interacts with the 3' border of the internal ribosomal entry site of hepatitis C virus. J. Virol., 72, 8782-8788.
30. Kim, C.S., Seol, S.K., Song, O.K., et al. (2007): An RNA-binding protein, hnRNP A1, and a scaffold protein, septin 6, facilitate hepatitis C virus replication. J. Virol., 81, 3852-3865.
31. Zhang, Z., Harris, D. and Pandey, V.N. (2008): The FUSE binding protein is a cellular factor required for efficient replication of hepatitis C virus. J. Virol., 82, 5761-5773.
32. Watashi, K., Ishii, N., Hijikata, M., et al. (2005): Cyclophilin B is a functional regulator of hepatitis C virus RNA polymerase. Mol. Cell, 19, 111-122.
33. Liu, Z., Yang, F., Robotham, J.M., et al. (2009): Critical role of cyclophilin A and its prolyl-peptidyl isomerase activity in the structure and function of the hepatitis C virus replication complex. J. Virol., 83, 6554-6565.
34. Kaul, A., Stauffer, S., Berger, C., et al. (2009): Essential role of cyclophilin A for hepatitis C virus replication and virus production and possible link to polyprotein cleavage kinetics. PLoS Pathog., 5, e1000546.
35. Okamoto, T., Nishimura, Y., Ichimura, T., et al. (2006): Hepatitis C virus RNA replication is regulated by FKBP8 and Hsp90. EMBO J., 25, 5015-5025.
36. Okamoto, T., Omori, H., Kaname, Y., et al. (2008): A singleamino-acid mutation in hepatitis C virus NS5A disrupting FKBP8 interaction impairs viral replication. J. Virol., 82, 3480-3489.
37. Nakagawa, S., Umehara, T., Matsuda, C., et al. (2007): Hsp90 inhibitors suppress HCV replication in replicon cells and humanized liver mice. Biochem. Biophys. Res. Commun., 353, 882-888.
38. Taguwa, S., Okamoto, T., Abe, T., et al. (2008): Human butyrate-induced transcript 1 interacts with hepatitis C virus NS5A and regulates viral replication. J. Virol., 82, 2631-2641.
39. Ujino, S., Yamaguchi, S., Shimotohno, K., et al. (2009): Heatshock protein 90 is essential for stabilization of the hepatitis C virus nonstructural protein NS3. J. Biol. Chem., 284, 6841-6846.
40. Taguwa, S., Kambara, H., Omori, H., et al. (2009): Cochaperone activity of human butyrate-induced transcript 1 facilitates hepatitis C virus replication through an Hsp90-dependent pathway. J. Virol., 83, 10427-10436.
41. Gao, L., Aizaki, H., He, J.W., et al. (2004): Interactions between viral nonstructural proteins and host protein hVAP-33 mediate the formation of hepatitis C virus RNA replication complex on lipid raft. J. Virol., 78, 3480-3488.
42. Hamamoto, I., Nishimura, Y., Okamoto, T., et al. (2005): Human VAP-B is involved in hepatitis C virus replication through interaction with NS5A and NS5B. J. Virol., 79, 13473-13482.
43. Ye, J., Wang, C., Sumpter, R., Jr., et al. (2003): Disruption of hepatitis C virus RNA replication through inhibition of host protein geranylgeranylation. Proc. Natl. Acad. Sci. USA, 100, 15865-15870.
44. Kapadia, S.B. and Chisari, F.V. (2005): Hepatitis C virus RNA replication is regulated by host geranylgeranylation and fatty acids. Proc. Natl. Acad. Sci. USA, 102, 2561-2566.
45. Wang, C., Gale, M., Keller, B.C., et al. (2005): Identification of FBL2 as a geranylgeranylated cellular protein required for hepatitis C virus RNA replication. Mol. Cell, 18, 425-434.
46. Kukihara, H., Moriishi, K., Taguwa, S., et al. (2009): Human VAP-C negatively regulates hepatitis C virus propagation. J. Virol., 83, 7959-7969.
47. Ikeda, M., Abe, K., Yamada, M., et al. (2006): Different anti-HCV profiles of statins and their potential for combination therapy with interferon. Hepatology, 44, 117-125.
48. Hara, H., Aizaki, H., Matsuda, M., et al. (2009): Involvement of creatine kinase B in hepatitis C virus genome replication through interaction with the viral NS4A protein. J. Virol., 83, 5137-5147.
49. Wakita, T., Pietschmann, T., Kato, T., et al. (2005): Production of infectious hepatitis C virus in tissue culture from a cloned viral genome. Nat. Med., 11, 791-796.
50. Zhong, J., Gastaminza, P., Cheng, G., et al. (2005): Robust hepatitis C virus infection in vitro. Proc. Natl. Acad. Sci. USA, 102, 9294-9299.
51. Lindenbach, B.D., Evans, M.J., Syder, A.J., et al. (2005): Complete replication of hepatitis C virus in cell culture. Science, 309, 623-626.
52. Lohmann, V., Korner, F., Koch, J., et al. (1999): Replication of subgenomic hepatitis C virus RNAs in a hepatoma cell line. Science, 285, 110-113.
53. Lan, S., Wang, H., Jiang, H., et al. (2003): Direct interaction between alpha-actinin and hepatitis C virus NS5B. FEBS Lett., 554, 289-294.
54. Ariumi, Y., Kuroki, M., Dansako, H., et al. (2008): The DNA damage sensors ataxia-telangiectasia mutated kinase and checkpoint kinase 2 are required for hepatitis C virus RNA replication. J. Virol., 82, 9639-9646.
55. Lai, C.K., Jeng, K.S., Machida, K., et al. (2008): Hepatitis C virus NS3/4A protein interacts with ATM, impairs DNA repair and enhances sensitivity to ionizing radiation. Virology, 370, 295-309.
56. Ariumi, Y., Kuroki, M., Abe, K., et al. (2007): DDX3 DEADbox RNA helicase is required for hepatitis C virus RNA replication. J. Virol., 81, 13922-13936.
57. Choi, Y.W., Tan, Y.J., Lim, S.G., et al. (2004): Proteomic approach identifies HSP27 as an interacting partner of the hepatitis C virus NS5A protein. Biochem. Biophys. Res. Commun., 318, 514-519.
58. Wu, X., Zhou, Y., Zhang, K., et al. (2008): Isoform-specific interaction of pyruvate kinase with hepatitis C virus NS5B. FEBS Lett., 582, 2155-2160.
59. Shimakami, T., Honda, M., Kusakawa, T., et al. (2006): Effect of hepatitis C virus (HCV) NS5B-nucleolin interaction on HCV replication with HCV subgenomic replicon. J. Virol., 80, 3332-3340.
60. Berger, K.L., Cooper, J.D., Heaton, N.S., et al. (2009): Roles for endocytic trafficking and phosphatidylinositol 4-kinase III alpha in hepatitis C virus replication. Proc. Natl. Acad. Sci. USA, 106, 7577-7582.
61. Ahn, J., Chung, K.S., Kim, D.U., et al. (2004): Systematic identification of hepatocellular proteins interacting with NS5A of the hepatitis C virus. J. Biochem. Mol. Biol., 37, 741-748.
62. Stone, M., Jia, S., Heo, W.D., et al. (2007): Participation of rab5, an early endosome protein, in hepatitis C virus RNA replication machinery. J. Virol., 81, 4551-4563.
63. Burckstummer, T., Kriegs, M. and Lupberger, J., (2006): Raf-1 kinase associates with hepatitis C virus NS5A and regulates viral replication. FEBS Lett., 580, 575-580.
64. Goh, P.Y., Tan, Y.J. and Lim, S.P. (2004): Cellular RNA helicase p68 relocalization and interaction with the hepatitis C virus (HCV) NS5B protein and the potential role of p68 in HCV RNA replication. J. Virol., 78, 5288-5298.
65. Sakamoto, H., Okamoto, K., Aoki, M., et al. (2005): Host sphingolipid biosynthesis as a target for hepatitis C virus therapy. Nat. Chem. Biol., 1, 333-337.
66. Liu, H.M., Aizaki, H., Choi, K.S., et al. (2009): SYNCRIP (synaptotagmin- binding, cytoplasmic RNA-interacting protein) is a host factor involved in hepatitis C virus RNA replication. Virology, 386, 249-256.
67. Kim, J.H., Paek, K.Y., Ha, S.H., et al. (2004): A cellular RNAbinding protein enhances internal ribosomal entry site-dependent translation through an interaction downstream of the hepatitis C virus polyprotein initiation codon. Mol. Cell Biol., 24, 7878-7890.
68. Sklan, E.H., Serrano, R.L., Einav, S., et al. (2007): TBC1D20 is a Rab1 GTPase-activating protein that mediates hepatitis C virus replication. J. Biol. Chem., 282, 36354-36361.
69. Park, K.J., Choi, S.H., Choi, D.H., et al. (2003): Hepatitis C virus NS5A protein modulates c-Jun N-terminal kinase through interaction with tumor necrosis factor receptor-associated factor 2. J. Biol. Chem., 278, 30711-30718.